Sartorius Stedim Biotech SA banner

Sartorius Stedim Biotech SA
PAR:DIM

Watchlist Manager
Sartorius Stedim Biotech SA Logo
Sartorius Stedim Biotech SA
PAR:DIM
Watchlist
Price: 164.5 EUR -1.53%
Market Cap: €16B

Sartorius Stedim Biotech SA
Total Equity

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
|
See Also

Sartorius Stedim Biotech SA
Total Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Equity CAGR 3Y CAGR 5Y CAGR 10Y
Sartorius Stedim Biotech SA
PAR:DIM
Total Equity
€4.1B
CAGR 3-Years
19%
CAGR 5-Years
23%
CAGR 10-Years
20%
Eurofins-Cerep SA
PAR:ALECR
Total Equity
€72m
CAGR 3-Years
17%
CAGR 5-Years
20%
CAGR 10-Years
19%
No Stocks Found

Sartorius Stedim Biotech SA
Glance View

Sartorius Stedim Biotech SA has been weaving the intricate threads of biotechnology innovation into a fabric of global influence and success. Established as a pivotal player in the biopharmaceutical industry, Sartorius Stedim Biotech has carved out a niche by offering sophisticated products and solutions that cater to the unique needs of biopharmaceutical manufacturers. The company’s portfolio is a testament to the fusion of scientific ingenuity and relentless pursuit of quality. Spanning filtration and purification solutions, fermentation equipment, and fluid management systems, their offerings ensure that complex biological drugs, including vaccines and monoclonal antibodies, are produced efficiently and safely. Sartorius Stedim Biotech’s endeavor is not just about supplying equipment; it’s about providing integrated solutions that optimize the entire production process, ensuring consistency, scalability, and compliance in industries bound by strict regulatory oversight. The company generated revenue through its comprehensive range of products and services that address every step of the biomanufacturing process. Their business model hinges on fostering long-term relationships with clients by offering tailored solutions that enhance productivity and reduce time-to-market for new therapies. Beyond direct sales of high-value equipment, Sartorius Stedim Biotech also capitalizes on recurring revenue streams generated from consumables and maintenance services essential for the ongoing operation of their systems. By continuously innovating and expanding its product lines, the company stays at the forefront of technological advancements, enabling clients to tackle the ever-evolving challenges of bioproduction. As the global biopharmaceutical industry surges forward, driven by increasing demand for biologics, Sartorius Stedim Biotech remains poised to maintain its role as an indispensable ally to firms dedicated to transforming the health landscape through revolutionary therapies.

DIM Intrinsic Value
136.9 EUR
Overvaluation 17%
Intrinsic Value
Price

See Also

What is Sartorius Stedim Biotech SA's Total Equity?
Total Equity
4.1B EUR

Based on the financial report for Dec 31, 2025, Sartorius Stedim Biotech SA's Total Equity amounts to 4.1B EUR.

What is Sartorius Stedim Biotech SA's Total Equity growth rate?
Total Equity CAGR 10Y
20%

Over the last year, the Total Equity growth was 3%. The average annual Total Equity growth rates for Sartorius Stedim Biotech SA have been 19% over the past three years , 23% over the past five years , and 20% over the past ten years .

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett